context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
Following the Spin-Off, which was completed pursuant to the Separation and Distribution Agreement, the Company had remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE was obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could have been obligated to make payments under the applicable instruments for which GE was obligated to reimburse and indemnify the Company. As of December 31, 2023, the Company’s maximum aggregate exposure, subject to GE reimbursement, was approximately $ 114 million. In the second quarter of 2024, these remaining performance guarantees were all terminated or replaced. | text | 114 | monetaryItemType | text: <entity> 114 </entity> <entity type> monetaryItemType </entity type> <context> Following the Spin-Off, which was completed pursuant to the Separation and Distribution Agreement, the Company had remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE was obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could have been obligated to make payments under the applicable instruments for which GE was obligated to reimburse and indemnify the Company. As of December 31, 2023, the Company’s maximum aggregate exposure, subject to GE reimbursement, was approximately $ 114 million. In the second quarter of 2024, these remaining performance guarantees were all terminated or replaced. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $ 16 million and $ 19 million as of December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. | text | 16 | monetaryItemType | text: <entity> 16 </entity> <entity type> monetaryItemType </entity type> <context> Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $ 16 million and $ 19 million as of December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. </context> | us-gaap:AccruedEnvironmentalLossContingenciesCurrent |
Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $ 16 million and $ 19 million as of December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. | text | 19 | monetaryItemType | text: <entity> 19 </entity> <entity type> monetaryItemType </entity type> <context> Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $ 16 million and $ 19 million as of December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. </context> | us-gaap:AccruedEnvironmentalLossContingenciesCurrent |
We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $ 292 million and $ 267 million at December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. | text | 292 | monetaryItemType | text: <entity> 292 </entity> <entity type> monetaryItemType </entity type> <context> We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $ 292 million and $ 267 million at December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. </context> | us-gaap:AssetRetirementObligation |
We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $ 292 million and $ 267 million at December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. | text | 267 | monetaryItemType | text: <entity> 267 </entity> <entity type> monetaryItemType </entity type> <context> We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $ 292 million and $ 267 million at December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. </context> | us-gaap:AssetRetirementObligation |
These restructuring initiatives are expected to result in additional expenses of approximately $ 36 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Consolidated and Combined Statements of Income. | text | 36 | monetaryItemType | text: <entity> 36 </entity> <entity type> monetaryItemType </entity type> <context> These restructuring initiatives are expected to result in additional expenses of approximately $ 36 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Consolidated and Combined Statements of Income. </context> | us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 |
We grant stock options, restricted stock units (“RSUs”), and performance share units (“PSUs”) to employees under the 2023 Long-Term Incentive Plan (“LTIP”). The Talent, Culture, and Compensation Committee of the Board of Directors approves grants under the LTIP. Under the LTIP, we are authorized to issue up to approximately 41 million shares. We record compensation expense for awards expected to vest over the vesting period. We estimate forfeitures based on experience and adjust expense to reflect actual forfeitures. When options are exercised, RSUs vest, and PSUs are earned, we issue shares from authorized unissued common stock. | text | 41 | sharesItemType | text: <entity> 41 </entity> <entity type> sharesItemType </entity type> <context> We grant stock options, restricted stock units (“RSUs”), and performance share units (“PSUs”) to employees under the 2023 Long-Term Incentive Plan (“LTIP”). The Talent, Culture, and Compensation Committee of the Board of Directors approves grants under the LTIP. Under the LTIP, we are authorized to issue up to approximately 41 million shares. We record compensation expense for awards expected to vest over the vesting period. We estimate forfeitures based on experience and adjust expense to reflect actual forfeitures. When options are exercised, RSUs vest, and PSUs are earned, we issue shares from authorized unissued common stock. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
Unrecognized compensation expense was $ 146 million as of December 31, 2024 and is expected to be recognized over a weighted-average period of approximately 1.8 years. | text | 146 | monetaryItemType | text: <entity> 146 </entity> <entity type> monetaryItemType </entity type> <context> Unrecognized compensation expense was $ 146 million as of December 31, 2024 and is expected to be recognized over a weighted-average period of approximately 1.8 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
On January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for the year ended December 31, 2022 was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date. | text | 454 | sharesItemType | text: <entity> 454 </entity> <entity type> sharesItemType </entity type> <context> On January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for the year ended December 31, 2022 was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date. </context> | us-gaap:CommonStockSharesOutstanding |
Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 268 | monetaryItemType | text: <entity> 268 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:Depreciation |
Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 248 | monetaryItemType | text: <entity> 248 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:Depreciation |
Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 228 | monetaryItemType | text: <entity> 228 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:Depreciation |
(2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $ 211 million was paid in the second quarter of 2023. | text | 211 | monetaryItemType | text: <entity> 211 </entity> <entity type> monetaryItemType </entity type> <context> (2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $ 211 million was paid in the second quarter of 2023. </context> | us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest |
As discussed in Note 10, “Postretirement Benefit Plans”, employees of the Company participated in pension, benefit, and contribution plans that were sponsored by GE. The Company was charged $ 207 million for the year ended December 31, 2022 related to employee participation in these plans. In connection with the Spin-Off, a portion of the plans were transferred to the Company. | text | 207 | monetaryItemType | text: <entity> 207 </entity> <entity type> monetaryItemType </entity type> <context> As discussed in Note 10, “Postretirement Benefit Plans”, employees of the Company participated in pension, benefit, and contribution plans that were sponsored by GE. The Company was charged $ 207 million for the year ended December 31, 2022 related to employee participation in these plans. In connection with the Spin-Off, a portion of the plans were transferred to the Company. </context> | us-gaap:RelatedPartyTransactionAmountsOfTransaction |
GE granted various employee benefits to its group employees, including those of the Company, under the GE Long-Term Incentive Plan. These benefits primarily included stock options and RSUs. Compensation expense allocated to the Company was $ 67 million for the year ended December 31, 2022, and was primarily recognized within SG&A in the Combined Statement of Income. | text | 67 | monetaryItemType | text: <entity> 67 </entity> <entity type> monetaryItemType </entity type> <context> GE granted various employee benefits to its group employees, including those of the Company, under the GE Long-Term Incentive Plan. These benefits primarily included stock options and RSUs. Compensation expense allocated to the Company was $ 67 million for the year ended December 31, 2022, and was primarily recognized within SG&A in the Combined Statement of Income. </context> | us-gaap:RelatedPartyTransactionAmountsOfTransaction |
– governs all matters relating to the provision of shared services between the Company and GE on a transitional basis. The services the Company receives include support for information technology, human resources, supply chain, finance, and facilities services, among others. Some of these costs were included in the allocations from GE prior to Spin-Off. The services generally commenced on the date of the Spin-Off and terminated in the 24 months following the Distribution Date depending upon the related transitional service. We incurred $ 172 million, n | text | 172 | monetaryItemType | text: <entity> 172 </entity> <entity type> monetaryItemType </entity type> <context> – governs all matters relating to the provision of shared services between the Company and GE on a transitional basis. The services the Company receives include support for information technology, human resources, supply chain, finance, and facilities services, among others. Some of these costs were included in the allocations from GE prior to Spin-Off. The services generally commenced on the date of the Spin-Off and terminated in the 24 months following the Distribution Date depending upon the related transitional service. We incurred $ 172 million, n </context> | us-gaap:RelatedPartyTransactionAmountsOfTransaction |
et, and $ 372 million, net, for the years ended December 31, 2024 and 2023, respectively, under this agreement. These amounts represent fees charged from GE and GE Vernova to the Company, the majority of which are related to information technology, and are net of fees charged from the Company to GE and GE Vernova for facilities and other shared services. | text | 372 | monetaryItemType | text: <entity> 372 </entity> <entity type> monetaryItemType </entity type> <context> et, and $ 372 million, net, for the years ended December 31, 2024 and 2023, respectively, under this agreement. These amounts represent fees charged from GE and GE Vernova to the Company, the majority of which are related to information technology, and are net of fees charged from the Company to GE and GE Vernova for facilities and other shared services. </context> | us-gaap:RelatedPartyTransactionAmountsOfTransaction |
On February 3, 2025, we repaid $ 250 million of the outstanding Term Loan Facility. | text | 250 | monetaryItemType | text: <entity> 250 </entity> <entity type> monetaryItemType </entity type> <context> On February 3, 2025, we repaid $ 250 million of the outstanding Term Loan Facility. </context> | us-gaap:RepaymentsOfLongTermDebt |
All advertising costs are expensed as incurred and reported within operating expenses on the Consolidated Statements of Operations. During the years ended December 31, 2024, 2023, and 2022, total advertising expense was $ 9 million, $ 8 million, and $ 8 million, respectively. | text | 9 | monetaryItemType | text: <entity> 9 </entity> <entity type> monetaryItemType </entity type> <context> All advertising costs are expensed as incurred and reported within operating expenses on the Consolidated Statements of Operations. During the years ended December 31, 2024, 2023, and 2022, total advertising expense was $ 9 million, $ 8 million, and $ 8 million, respectively. </context> | us-gaap:AdvertisingExpense |
All advertising costs are expensed as incurred and reported within operating expenses on the Consolidated Statements of Operations. During the years ended December 31, 2024, 2023, and 2022, total advertising expense was $ 9 million, $ 8 million, and $ 8 million, respectively. | text | 8 | monetaryItemType | text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> All advertising costs are expensed as incurred and reported within operating expenses on the Consolidated Statements of Operations. During the years ended December 31, 2024, 2023, and 2022, total advertising expense was $ 9 million, $ 8 million, and $ 8 million, respectively. </context> | us-gaap:AdvertisingExpense |
Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100 % owner of Healthpeak OP. Subsequent to the Reorganization, certain employees of the Company (“OP Unitholders”) were issued noncontrolling, non-managing member units in Healthpeak OP (“OP Units”). When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of the Company’s common stock, at the Company’s option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of the Company’s common stock or cash equal to the fair value of a share of common stock at the time of redemption. The Company classifies the OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their OP Units rather than using cash. | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100 % owner of Healthpeak OP. Subsequent to the Reorganization, certain employees of the Company (“OP Unitholders”) were issued noncontrolling, non-managing member units in Healthpeak OP (“OP Units”). When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of the Company’s common stock, at the Company’s option as managing member of Healthpeak OP. The per unit redemption amount is equal to either one share of the Company’s common stock or cash equal to the fair value of a share of common stock at the time of redemption. The Company classifies the OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their OP Units rather than using cash. </context> | us-gaap:MinorityInterestOwnershipPercentageByParent |
Includes 241 million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares outstanding as of March 1, 2024, inclusive of: (i) 200 thousand Physicians Realty Trust restricted shares; (ii) 1 million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit (“PSUs”) (reflected at the maximum level of performance); and (iii) 300 thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units (“RSUs”). | text | 200 | sharesItemType | text: <entity> 200 </entity> <entity type> sharesItemType </entity type> <context> Includes 241 million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares outstanding as of March 1, 2024, inclusive of: (i) 200 thousand Physicians Realty Trust restricted shares; (ii) 1 million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit (“PSUs”) (reflected at the maximum level of performance); and (iii) 300 thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units (“RSUs”). </context> | us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued |
Includes 241 million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares outstanding as of March 1, 2024, inclusive of: (i) 200 thousand Physicians Realty Trust restricted shares; (ii) 1 million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit (“PSUs”) (reflected at the maximum level of performance); and (iii) 300 thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units (“RSUs”). | text | 1 | sharesItemType | text: <entity> 1 </entity> <entity type> sharesItemType </entity type> <context> Includes 241 million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares outstanding as of March 1, 2024, inclusive of: (i) 200 thousand Physicians Realty Trust restricted shares; (ii) 1 million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit (“PSUs”) (reflected at the maximum level of performance); and (iii) 300 thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units (“RSUs”). </context> | us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued |
Includes 241 million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares outstanding as of March 1, 2024, inclusive of: (i) 200 thousand Physicians Realty Trust restricted shares; (ii) 1 million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit (“PSUs”) (reflected at the maximum level of performance); and (iii) 300 thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units (“RSUs”). | text | 300 | sharesItemType | text: <entity> 300 </entity> <entity type> sharesItemType </entity type> <context> Includes 241 million Physicians Realty Trust common shares and Physicians Realty Trust restricted shares outstanding as of March 1, 2024, inclusive of: (i) 200 thousand Physicians Realty Trust restricted shares; (ii) 1 million Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust performance-based restricted stock unit (“PSUs”) (reflected at the maximum level of performance); and (iii) 300 thousand Physicians Realty Trust common shares issuable pursuant to outstanding Physicians Realty Trust restricted stock units (“RSUs”). </context> | us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued |
Includes $ 14 million of gross contractual accounts receivable. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 14 million of gross contractual accounts receivable. </context> | us-gaap:BusinessCombinationAcquiredReceivablesGrossContractualAmount |
Includes six consolidated joint ventures in which the Company held ownership interests ranging from 56.7 % to 99.7 % on the Closing Date. | text | 56.7 | percentItemType | text: <entity> 56.7 </entity> <entity type> percentItemType </entity type> <context> Includes six consolidated joint ventures in which the Company held ownership interests ranging from 56.7 % to 99.7 % on the Closing Date. </context> | us-gaap:VariableInterestEntityOwnershipPercentage |
Includes six consolidated joint ventures in which the Company held ownership interests ranging from 56.7 % to 99.7 % on the Closing Date. | text | 99.7 | percentItemType | text: <entity> 99.7 </entity> <entity type> percentItemType </entity type> <context> Includes six consolidated joint ventures in which the Company held ownership interests ranging from 56.7 % to 99.7 % on the Closing Date. </context> | us-gaap:VariableInterestEntityOwnershipPercentage |
The measurement period adjustments recorded through December 31, 2024 are final and were primarily the result of additional information obtained during the measurement period by the Company related to certain assets acquired and liabilities assumed and updated valuations of noncontrolling interests, resulting in an increase to goodwill of $ 3 million. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> The measurement period adjustments recorded through December 31, 2024 are final and were primarily the result of additional information obtained during the measurement period by the Company related to certain assets acquired and liabilities assumed and updated valuations of noncontrolling interests, resulting in an increase to goodwill of $ 3 million. </context> | us-gaap:Goodwill |
$ 38 million of fees paid to investment banks and advisors to help the Company negotiate the terms of the transactions contemplated by the Merger Agreement and to advise the Company on other merger-related matters, inclusive of | text | 38 | monetaryItemType | text: <entity> 38 </entity> <entity type> monetaryItemType </entity type> <context> $ 38 million of fees paid to investment banks and advisors to help the Company negotiate the terms of the transactions contemplated by the Merger Agreement and to advise the Company on other merger-related matters, inclusive of </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
$ 21 million of success-based fees incurred upon consummation of the Merger, (ii) | text | 21 | monetaryItemType | text: <entity> 21 </entity> <entity type> monetaryItemType </entity type> <context> $ 21 million of success-based fees incurred upon consummation of the Merger, (ii) </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
$ 26 million of severance expense due to certain Physicians Realty Trust dual-trigger severance arrangements that are required to be recognized as post-combination expense in accordance with ASC 805, (iii) | text | 26 | monetaryItemType | text: <entity> 26 </entity> <entity type> monetaryItemType </entity type> <context> $ 26 million of severance expense due to certain Physicians Realty Trust dual-trigger severance arrangements that are required to be recognized as post-combination expense in accordance with ASC 805, (iii) </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
$ 16 million of post-combination stock compensation expense for the accelerated vesting of Physicians Realty Trust equity awards pursuant to the terms of the Merger Agreement, based on the fair value of Healthpeak common stock issued to holders of Physicians Realty Trust equity awards, (iv) | text | 16 | monetaryItemType | text: <entity> 16 </entity> <entity type> monetaryItemType </entity type> <context> $ 16 million of post-combination stock compensation expense for the accelerated vesting of Physicians Realty Trust equity awards pursuant to the terms of the Merger Agreement, based on the fair value of Healthpeak common stock issued to holders of Physicians Realty Trust equity awards, (iv) </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
$ 13 million of severance expense related to legacy Healthpeak employees. During the year ended December 31, 2023, the Company incurred approximately $ 11 million of merger-related costs, which primarily related to advisory, legal, accounting, tax, and other costs. These merger-related costs are included in transaction and merger-related costs on the Consolidated Statements of Operations. | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> $ 13 million of severance expense related to legacy Healthpeak employees. During the year ended December 31, 2023, the Company incurred approximately $ 11 million of merger-related costs, which primarily related to advisory, legal, accounting, tax, and other costs. These merger-related costs are included in transaction and merger-related costs on the Consolidated Statements of Operations. </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
$ 13 million of severance expense related to legacy Healthpeak employees. During the year ended December 31, 2023, the Company incurred approximately $ 11 million of merger-related costs, which primarily related to advisory, legal, accounting, tax, and other costs. These merger-related costs are included in transaction and merger-related costs on the Consolidated Statements of Operations. | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> $ 13 million of severance expense related to legacy Healthpeak employees. During the year ended December 31, 2023, the Company incurred approximately $ 11 million of merger-related costs, which primarily related to advisory, legal, accounting, tax, and other costs. These merger-related costs are included in transaction and merger-related costs on the Consolidated Statements of Operations. </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
$ 6 million of net loss applicable to common shares associated with the results of operations of legacy Physicians Realty Trust from the Closing Date to | text | 6 | monetaryItemType | text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> $ 6 million of net loss applicable to common shares associated with the results of operations of legacy Physicians Realty Trust from the Closing Date to </context> | us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual |
$ 129 million that were incurred during the year ended December 31, 2024, | text | 129 | monetaryItemType | text: <entity> 129 </entity> <entity type> monetaryItemType </entity type> <context> $ 129 million that were incurred during the year ended December 31, 2024, </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
December 31, 2023 also includes $ 11 million of transaction and merger-related costs that were recognized during the year then ended. | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> December 31, 2023 also includes $ 11 million of transaction and merger-related costs that were recognized during the year then ended. </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
In January 2023, the Company acquired a lab land parcel in Cambridge, Massachusetts for $ 9 million. | text | 9 | monetaryItemType | text: <entity> 9 </entity> <entity type> monetaryItemType </entity type> <context> In January 2023, the Company acquired a lab land parcel in Cambridge, Massachusetts for $ 9 million. </context> | us-gaap:PaymentsToAcquireRealEstate |
In April 2023, the Company acquired the remaining 80 % interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of $ 0.2 million, which is recorded in other income (expense), net during the year ended December 31, 2023. | text | 80 | percentItemType | text: <entity> 80 </entity> <entity type> percentItemType </entity type> <context> In April 2023, the Company acquired the remaining 80 % interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of $ 0.2 million, which is recorded in other income (expense), net during the year ended December 31, 2023. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
In April 2023, the Company acquired the remaining 80 % interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of $ 0.2 million, which is recorded in other income (expense), net during the year ended December 31, 2023. | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> In April 2023, the Company acquired the remaining 80 % interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of $ 0.2 million, which is recorded in other income (expense), net during the year ended December 31, 2023. </context> | us-gaap:NumberOfRealEstateProperties |
In April 2023, the Company acquired the remaining 80 % interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of $ 0.2 million, which is recorded in other income (expense), net during the year ended December 31, 2023. | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> In April 2023, the Company acquired the remaining 80 % interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of $ 0.2 million, which is recorded in other income (expense), net during the year ended December 31, 2023. </context> | us-gaap:PaymentsToAcquireEquityMethodInvestments |
In April 2023, the Company acquired the remaining 80 % interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of $ 0.2 million, which is recorded in other income (expense), net during the year ended December 31, 2023. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> In April 2023, the Company acquired the remaining 80 % interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $ 4 million (see Note 9). Concurrent with the acquisition, the Company began consolidating the building and recognized a gain upon change of control of $ 0.2 million, which is recorded in other income (expense), net during the year ended December 31, 2023. </context> | us-gaap:GainLossOnInvestments |
In January 2022, the Company closed a lab acquisition in Cambridge, Massachusetts for $ 72 million. | text | 72 | monetaryItemType | text: <entity> 72 </entity> <entity type> monetaryItemType </entity type> <context> In January 2022, the Company closed a lab acquisition in Cambridge, Massachusetts for $ 72 million. </context> | us-gaap:PaymentsToAcquireRealEstate |
In January 2022, the Company closed a lab acquisition in San Diego, California for $ 24 million. | text | 24 | monetaryItemType | text: <entity> 24 </entity> <entity type> monetaryItemType </entity type> <context> In January 2022, the Company closed a lab acquisition in San Diego, California for $ 24 million. </context> | us-gaap:PaymentsToAcquireRealEstate |
In March 2022, the Company acquired a portfolio of two outpatient medical buildings in Houston, Texas for $ 43 million. | text | 43 | monetaryItemType | text: <entity> 43 </entity> <entity type> monetaryItemType </entity type> <context> In March 2022, the Company acquired a portfolio of two outpatient medical buildings in Houston, Texas for $ 43 million. </context> | us-gaap:PaymentsToAcquireRealEstate |
In May 2022, the Company acquired one outpatient medical building in Bentonville, Arkansas for $ 26 million. | text | 26 | monetaryItemType | text: <entity> 26 </entity> <entity type> monetaryItemType </entity type> <context> In May 2022, the Company acquired one outpatient medical building in Bentonville, Arkansas for $ 26 million. </context> | us-gaap:PaymentsToAcquireRealEstate |
In December 2022, the Company closed a lab acquisition in Cambridge, Massachusetts for $ 18 million. | text | 18 | monetaryItemType | text: <entity> 18 </entity> <entity type> monetaryItemType </entity type> <context> In December 2022, the Company closed a lab acquisition in Cambridge, Massachusetts for $ 18 million. </context> | us-gaap:PaymentsToAcquireRealEstate |
During the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for $ 674 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million (see Note 8), (ii) 14 outpatient medical buildings for $ 220 million, (iii) a portfolio of seven lab buildings for $ 180 million, (iv) a portfolio of two outpatient medical buildings for $ 23 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 14 million | text | 674 | monetaryItemType | text: <entity> 674 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for $ 674 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million (see Note 8), (ii) 14 outpatient medical buildings for $ 220 million, (iii) a portfolio of seven lab buildings for $ 180 million, (iv) a portfolio of two outpatient medical buildings for $ 23 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 14 million </context> | us-gaap:ProceedsFromSaleOfBuildings |
During the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for $ 674 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million (see Note 8), (ii) 14 outpatient medical buildings for $ 220 million, (iii) a portfolio of seven lab buildings for $ 180 million, (iv) a portfolio of two outpatient medical buildings for $ 23 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 14 million | text | 220 | monetaryItemType | text: <entity> 220 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for $ 674 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million (see Note 8), (ii) 14 outpatient medical buildings for $ 220 million, (iii) a portfolio of seven lab buildings for $ 180 million, (iv) a portfolio of two outpatient medical buildings for $ 23 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 14 million </context> | us-gaap:ProceedsFromSaleOfBuildings |
During the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for $ 674 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million (see Note 8), (ii) 14 outpatient medical buildings for $ 220 million, (iii) a portfolio of seven lab buildings for $ 180 million, (iv) a portfolio of two outpatient medical buildings for $ 23 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 14 million | text | 180 | monetaryItemType | text: <entity> 180 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for $ 674 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million (see Note 8), (ii) 14 outpatient medical buildings for $ 220 million, (iii) a portfolio of seven lab buildings for $ 180 million, (iv) a portfolio of two outpatient medical buildings for $ 23 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 14 million </context> | us-gaap:ProceedsFromSaleOfBuildings |
During the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for $ 674 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million (see Note 8), (ii) 14 outpatient medical buildings for $ 220 million, (iii) a portfolio of seven lab buildings for $ 180 million, (iv) a portfolio of two outpatient medical buildings for $ 23 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 14 million | text | 23 | monetaryItemType | text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company sold: (i) a portfolio of 59 outpatient medical buildings for $ 674 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 405 million (see Note 8), (ii) 14 outpatient medical buildings for $ 220 million, (iii) a portfolio of seven lab buildings for $ 180 million, (iv) a portfolio of two outpatient medical buildings for $ 23 million and provided the buyer with a mortgage loan secured by the real estate sold for $ 14 million </context> | us-gaap:ProceedsFromSaleOfBuildings |
(see Note 8), and (v) a portfolio comprised of a land parcel and various vacant buildings on certain of the Company’s CCRC campuses for $ 12 million, resulting in total net gain on sales of $ 179 million. | text | 12 | monetaryItemType | text: <entity> 12 </entity> <entity type> monetaryItemType </entity type> <context> (see Note 8), and (v) a portfolio comprised of a land parcel and various vacant buildings on certain of the Company’s CCRC campuses for $ 12 million, resulting in total net gain on sales of $ 179 million. </context> | us-gaap:ProceedsFromSaleOfBuildings |
(see Note 8), and (v) a portfolio comprised of a land parcel and various vacant buildings on certain of the Company’s CCRC campuses for $ 12 million, resulting in total net gain on sales of $ 179 million. | text | 179 | monetaryItemType | text: <entity> 179 </entity> <entity type> monetaryItemType </entity type> <context> (see Note 8), and (v) a portfolio comprised of a land parcel and various vacant buildings on certain of the Company’s CCRC campuses for $ 12 million, resulting in total net gain on sales of $ 179 million. </context> | us-gaap:GainsLossesOnSalesOfInvestmentRealEstate |
During the year ended December 31, 2023, the Company sold two lab buildings in Durham, North Carolina, for $ 113 million and two outpatient medical buildings for $ 32 million, resulting in total gain on sales of $ 81 million. | text | 113 | monetaryItemType | text: <entity> 113 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, the Company sold two lab buildings in Durham, North Carolina, for $ 113 million and two outpatient medical buildings for $ 32 million, resulting in total gain on sales of $ 81 million. </context> | us-gaap:ProceedsFromSaleOfBuildings |
During the year ended December 31, 2023, the Company sold two lab buildings in Durham, North Carolina, for $ 113 million and two outpatient medical buildings for $ 32 million, resulting in total gain on sales of $ 81 million. | text | 32 | monetaryItemType | text: <entity> 32 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, the Company sold two lab buildings in Durham, North Carolina, for $ 113 million and two outpatient medical buildings for $ 32 million, resulting in total gain on sales of $ 81 million. </context> | us-gaap:ProceedsFromSaleOfBuildings |
During the year ended December 31, 2023, the Company sold two lab buildings in Durham, North Carolina, for $ 113 million and two outpatient medical buildings for $ 32 million, resulting in total gain on sales of $ 81 million. | text | 81 | monetaryItemType | text: <entity> 81 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, the Company sold two lab buildings in Durham, North Carolina, for $ 113 million and two outpatient medical buildings for $ 32 million, resulting in total gain on sales of $ 81 million. </context> | us-gaap:GainsLossesOnSalesOfInvestmentRealEstate |
During the year ended December 31, 2022, the Company sold one lab building in Salt Lake City, Utah for $ 14 million and five outpatient medical buildings and one outpatient medical land parcel for $ 36 million, resulting in total gain on sales of $ 15 million. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company sold one lab building in Salt Lake City, Utah for $ 14 million and five outpatient medical buildings and one outpatient medical land parcel for $ 36 million, resulting in total gain on sales of $ 15 million. </context> | us-gaap:ProceedsFromSaleOfBuildings |
During the year ended December 31, 2022, the Company sold one lab building in Salt Lake City, Utah for $ 14 million and five outpatient medical buildings and one outpatient medical land parcel for $ 36 million, resulting in total gain on sales of $ 15 million. | text | 36 | monetaryItemType | text: <entity> 36 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company sold one lab building in Salt Lake City, Utah for $ 14 million and five outpatient medical buildings and one outpatient medical land parcel for $ 36 million, resulting in total gain on sales of $ 15 million. </context> | us-gaap:ProceedsFromSaleOfBuildings |
During the year ended December 31, 2022, the Company sold one lab building in Salt Lake City, Utah for $ 14 million and five outpatient medical buildings and one outpatient medical land parcel for $ 36 million, resulting in total gain on sales of $ 15 million. | text | 15 | monetaryItemType | text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company sold one lab building in Salt Lake City, Utah for $ 14 million and five outpatient medical buildings and one outpatient medical land parcel for $ 36 million, resulting in total gain on sales of $ 15 million. </context> | us-gaap:GainsLossesOnSalesOfInvestmentRealEstate |
outpatient medical building was classified as held for sale, with a carrying value of $ 8 million, primarily comprised of net real estate assets. As of December 31, 2024, liabilities related to the asset held for sale were | text | 8 | monetaryItemType | text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> outpatient medical building was classified as held for sale, with a carrying value of $ 8 million, primarily comprised of net real estate assets. As of December 31, 2024, liabilities related to the asset held for sale were </context> | us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup |
zero . As of December 31, 2023, two lab buildings | text | zero | monetaryItemType | text: <entity> zero </entity> <entity type> monetaryItemType </entity type> <context> zero . As of December 31, 2023, two lab buildings </context> | us-gaap:RealEstateLiabilitiesAssociatedWithAssetsHeldForDevelopmentAndSale |
and one outpatient medical building were classified as held for sale, with a carrying value of $ 118 million, primarily comprised of net real estate assets. As of December 31, 2023, liabilities related to the assets held for sale were $ 1 million. During the three months ended March 31, 2024, the Company sold the outpatient medical building and a 65 % interest in the two lab buildings (see Note 9) that were classified as held for sale as of December 31, 2023. | text | 118 | monetaryItemType | text: <entity> 118 </entity> <entity type> monetaryItemType </entity type> <context> and one outpatient medical building were classified as held for sale, with a carrying value of $ 118 million, primarily comprised of net real estate assets. As of December 31, 2023, liabilities related to the assets held for sale were $ 1 million. During the three months ended March 31, 2024, the Company sold the outpatient medical building and a 65 % interest in the two lab buildings (see Note 9) that were classified as held for sale as of December 31, 2023. </context> | us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup |
and one outpatient medical building were classified as held for sale, with a carrying value of $ 118 million, primarily comprised of net real estate assets. As of December 31, 2023, liabilities related to the assets held for sale were $ 1 million. During the three months ended March 31, 2024, the Company sold the outpatient medical building and a 65 % interest in the two lab buildings (see Note 9) that were classified as held for sale as of December 31, 2023. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> and one outpatient medical building were classified as held for sale, with a carrying value of $ 118 million, primarily comprised of net real estate assets. As of December 31, 2023, liabilities related to the assets held for sale were $ 1 million. During the three months ended March 31, 2024, the Company sold the outpatient medical building and a 65 % interest in the two lab buildings (see Note 9) that were classified as held for sale as of December 31, 2023. </context> | us-gaap:RealEstateLiabilitiesAssociatedWithAssetsHeldForDevelopmentAndSale |
and one outpatient medical building were classified as held for sale, with a carrying value of $ 118 million, primarily comprised of net real estate assets. As of December 31, 2023, liabilities related to the assets held for sale were $ 1 million. During the three months ended March 31, 2024, the Company sold the outpatient medical building and a 65 % interest in the two lab buildings (see Note 9) that were classified as held for sale as of December 31, 2023. | text | 65 | percentItemType | text: <entity> 65 </entity> <entity type> percentItemType </entity type> <context> and one outpatient medical building were classified as held for sale, with a carrying value of $ 118 million, primarily comprised of net real estate assets. As of December 31, 2023, liabilities related to the assets held for sale were $ 1 million. During the three months ended March 31, 2024, the Company sold the outpatient medical building and a 65 % interest in the two lab buildings (see Note 9) that were classified as held for sale as of December 31, 2023. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
During the year ended December 31, 2024, the Company recognized an impairment charge of $ 13 million, which is reported in impairments and loan loss reserves (recoveries), net, on the Consolidated Statements of Operations related to | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company recognized an impairment charge of $ 13 million, which is reported in impairments and loan loss reserves (recoveries), net, on the Consolidated Statements of Operations related to </context> | us-gaap:ImpairmentOfRealEstate |
one outpatient medical building that met the held for sale criteria. Upon classifying the asset as held for sale, the Company recognized an impairment charge to write down the building’s carrying value of $ 21 million to its fair value, less estimated costs to sell, of $ 8 million. | text | 8 | monetaryItemType | text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> one outpatient medical building that met the held for sale criteria. Upon classifying the asset as held for sale, the Company recognized an impairment charge to write down the building’s carrying value of $ 21 million to its fair value, less estimated costs to sell, of $ 8 million. </context> | us-gaap:RealEstateHeldforsale |
During the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 30 million, $( 3 ) million, and $ 6 million, respectively, of net casualty-related charges (recoveries). During the year ended December 31, 2024, such charges were primarily related to | text | 30 | monetaryItemType | text: <entity> 30 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 30 million, $( 3 ) million, and $ 6 million, respectively, of net casualty-related charges (recoveries). During the year ended December 31, 2024, such charges were primarily related to </context> | us-gaap:InsuredEventGainLoss |
During the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 30 million, $( 3 ) million, and $ 6 million, respectively, of net casualty-related charges (recoveries). During the year ended December 31, 2024, such charges were primarily related to | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 30 million, $( 3 ) million, and $ 6 million, respectively, of net casualty-related charges (recoveries). During the year ended December 31, 2024, such charges were primarily related to </context> | us-gaap:InsuredEventGainLoss |
During the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 30 million, $( 3 ) million, and $ 6 million, respectively, of net casualty-related charges (recoveries). During the year ended December 31, 2024, such charges were primarily related to | text | 6 | monetaryItemType | text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023, and 2022, the Company recognized $ 30 million, $( 3 ) million, and $ 6 million, respectively, of net casualty-related charges (recoveries). During the year ended December 31, 2024, such charges were primarily related to </context> | us-gaap:InsuredEventGainLoss |
$ 0.7 million, $ 4 million, and $ 3 million, respectively, which are recognized in rental and related revenues and resident fees and services on the Consolidated Statements of Operations. | text | 0.7 | monetaryItemType | text: <entity> 0.7 </entity> <entity type> monetaryItemType </entity type> <context> $ 0.7 million, $ 4 million, and $ 3 million, respectively, which are recognized in rental and related revenues and resident fees and services on the Consolidated Statements of Operations. </context> | us-gaap:InsuredEventGainLoss |
$ 0.7 million, $ 4 million, and $ 3 million, respectively, which are recognized in rental and related revenues and resident fees and services on the Consolidated Statements of Operations. | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> $ 0.7 million, $ 4 million, and $ 3 million, respectively, which are recognized in rental and related revenues and resident fees and services on the Consolidated Statements of Operations. </context> | us-gaap:InsuredEventGainLoss |
$ 0.7 million, $ 4 million, and $ 3 million, respectively, which are recognized in rental and related revenues and resident fees and services on the Consolidated Statements of Operations. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> $ 0.7 million, $ 4 million, and $ 3 million, respectively, which are recognized in rental and related revenues and resident fees and services on the Consolidated Statements of Operations. </context> | us-gaap:InsuredEventGainLoss |
During the year ended December 31, 2022, the Company recognized $ 14 million of expenses within other income (expense), net on the Consolidated Statements of Operations for tenant relocation and other costs associated with the demolition of an outpatient medical building. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company recognized $ 14 million of expenses within other income (expense), net on the Consolidated Statements of Operations for tenant relocation and other costs associated with the demolition of an outpatient medical building. </context> | us-gaap:OtherNonrecurringExpense |
During the first quarter of 2022, the Company sold its remaining hospital under a DFL for $ 68 million and recognized a gain on sale of $ 23 million, which is included in other income (expense), net on the Consolidated Statements of Operations. Therefore, at December 31, 2024 and 2023, the Company had no leases classified as a DFL. | text | 68 | monetaryItemType | text: <entity> 68 </entity> <entity type> monetaryItemType </entity type> <context> During the first quarter of 2022, the Company sold its remaining hospital under a DFL for $ 68 million and recognized a gain on sale of $ 23 million, which is included in other income (expense), net on the Consolidated Statements of Operations. Therefore, at December 31, 2024 and 2023, the Company had no leases classified as a DFL. </context> | us-gaap:ProceedsFromSaleOfLeaseReceivables |
During the first quarter of 2022, the Company sold its remaining hospital under a DFL for $ 68 million and recognized a gain on sale of $ 23 million, which is included in other income (expense), net on the Consolidated Statements of Operations. Therefore, at December 31, 2024 and 2023, the Company had no leases classified as a DFL. | text | 23 | monetaryItemType | text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> During the first quarter of 2022, the Company sold its remaining hospital under a DFL for $ 68 million and recognized a gain on sale of $ 23 million, which is included in other income (expense), net on the Consolidated Statements of Operations. Therefore, at December 31, 2024 and 2023, the Company had no leases classified as a DFL. </context> | us-gaap:GainLossOnSaleOfNotesReceivable |
While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. | text | 38 | monetaryItemType | text: <entity> 38 </entity> <entity type> monetaryItemType </entity type> <context> While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. </context> | us-gaap:PropertyPlantAndEquipmentGross |
While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. | text | 39 | monetaryItemType | text: <entity> 39 </entity> <entity type> monetaryItemType </entity type> <context> While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. </context> | us-gaap:PropertyPlantAndEquipmentGross |
While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. | text | 8 | monetaryItemType | text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. </context> | us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. | text | 10 | monetaryItemType | text: <entity> 10 </entity> <entity type> monetaryItemType </entity type> <context> While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. </context> | us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. </context> | us-gaap:Depreciation |
While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> While the Company leases the majority of its property, plant, and equipment to various tenants under operating leases, in certain situations, the Company owns and operates certain property, plant, and equipment for general corporate purposes. Corporate assets are recorded within other assets, net within the Company’s Consolidated Balance Sheets and depreciation expense for those assets is recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations. As of December 31, 2024 and 2023, the Company had $ 38 million and $ 39 million of corporate assets, respectively. Also included within other assets, net as of December 31, 2024 and 2023 is $ 8 million and $ 10 million, respectively, of accumulated depreciation related to corporate assets. Included within general and administrative expenses for the years ended December 31, 2024, 2023, and 2022 is $ 2 million, $ 3 million, and $ 3 million, respectively, of depreciation expense related to corporate assets. </context> | us-gaap:Depreciation |
During the year ended December 31, 2022, the Company recognized $ 7 million of charges in connection with the downsizing of the Company’s corporate headquarters in Denver, Colorado which are included in general and administrative expenses on the Consolidated Statements of Operations. | text | 7 | monetaryItemType | text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company recognized $ 7 million of charges in connection with the downsizing of the Company’s corporate headquarters in Denver, Colorado which are included in general and administrative expenses on the Consolidated Statements of Operations. </context> | us-gaap:GeneralAndAdministrativeExpense |
During the first quarter of 2023, the Company wrote off $ 9 million of straight-line rent receivable associated with four in-place operating leases with Sorrento Therapeutics, Inc. (“Sorrento”), which commenced voluntary reorganization proceedings (the “Filing”) under Chapter 11 of the U.S. Bankruptcy Code during the period. This write-off was recognized as a reduction in rental and related revenues on the Consolidated Statements of Operations. Subsequent to the write-off, revenue related to this tenant is recognized on a cash basis. Sorrento also had a single development lease with the Company, but had not taken occupancy at the time of the Filing. The Company has filed proofs of claims for damages related to its rejected leases, which include the development lease and three of the four operating leases. The Company filed proofs of claim for related damages during the year ended December 31, 2023, $ 4 million of which was received by the Company by drawing on Sorrento’s letters of credit and security deposits. These cash proceeds were recognized as lease termination fee income, which is included in rental and related revenues on the Consolidated Statements of Operations. In April 2024, the U.S. Bankruptcy Court approved the assignment and assumption of the remaining operating lease by the buyer of Sorrento’s assets. Given the nature of bankruptcy proceedings, the probability, timing, and amount of the additional proceeds, if any, that the Company may ultimately receive in connection with the claims are uncertain. Accordingly, the Company has not recorded any estimated recoveries associated with these claims as of December 31, 2024 or December 31, 2023. | text | 9 | monetaryItemType | text: <entity> 9 </entity> <entity type> monetaryItemType </entity type> <context> During the first quarter of 2023, the Company wrote off $ 9 million of straight-line rent receivable associated with four in-place operating leases with Sorrento Therapeutics, Inc. (“Sorrento”), which commenced voluntary reorganization proceedings (the “Filing”) under Chapter 11 of the U.S. Bankruptcy Code during the period. This write-off was recognized as a reduction in rental and related revenues on the Consolidated Statements of Operations. Subsequent to the write-off, revenue related to this tenant is recognized on a cash basis. Sorrento also had a single development lease with the Company, but had not taken occupancy at the time of the Filing. The Company has filed proofs of claims for damages related to its rejected leases, which include the development lease and three of the four operating leases. The Company filed proofs of claim for related damages during the year ended December 31, 2023, $ 4 million of which was received by the Company by drawing on Sorrento’s letters of credit and security deposits. These cash proceeds were recognized as lease termination fee income, which is included in rental and related revenues on the Consolidated Statements of Operations. In April 2024, the U.S. Bankruptcy Court approved the assignment and assumption of the remaining operating lease by the buyer of Sorrento’s assets. Given the nature of bankruptcy proceedings, the probability, timing, and amount of the additional proceeds, if any, that the Company may ultimately receive in connection with the claims are uncertain. Accordingly, the Company has not recorded any estimated recoveries associated with these claims as of December 31, 2024 or December 31, 2023. </context> | us-gaap:StraightLineRent |
During the first quarter of 2023, the Company wrote off $ 9 million of straight-line rent receivable associated with four in-place operating leases with Sorrento Therapeutics, Inc. (“Sorrento”), which commenced voluntary reorganization proceedings (the “Filing”) under Chapter 11 of the U.S. Bankruptcy Code during the period. This write-off was recognized as a reduction in rental and related revenues on the Consolidated Statements of Operations. Subsequent to the write-off, revenue related to this tenant is recognized on a cash basis. Sorrento also had a single development lease with the Company, but had not taken occupancy at the time of the Filing. The Company has filed proofs of claims for damages related to its rejected leases, which include the development lease and three of the four operating leases. The Company filed proofs of claim for related damages during the year ended December 31, 2023, $ 4 million of which was received by the Company by drawing on Sorrento’s letters of credit and security deposits. These cash proceeds were recognized as lease termination fee income, which is included in rental and related revenues on the Consolidated Statements of Operations. In April 2024, the U.S. Bankruptcy Court approved the assignment and assumption of the remaining operating lease by the buyer of Sorrento’s assets. Given the nature of bankruptcy proceedings, the probability, timing, and amount of the additional proceeds, if any, that the Company may ultimately receive in connection with the claims are uncertain. Accordingly, the Company has not recorded any estimated recoveries associated with these claims as of December 31, 2024 or December 31, 2023. | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> During the first quarter of 2023, the Company wrote off $ 9 million of straight-line rent receivable associated with four in-place operating leases with Sorrento Therapeutics, Inc. (“Sorrento”), which commenced voluntary reorganization proceedings (the “Filing”) under Chapter 11 of the U.S. Bankruptcy Code during the period. This write-off was recognized as a reduction in rental and related revenues on the Consolidated Statements of Operations. Subsequent to the write-off, revenue related to this tenant is recognized on a cash basis. Sorrento also had a single development lease with the Company, but had not taken occupancy at the time of the Filing. The Company has filed proofs of claims for damages related to its rejected leases, which include the development lease and three of the four operating leases. The Company filed proofs of claim for related damages during the year ended December 31, 2023, $ 4 million of which was received by the Company by drawing on Sorrento’s letters of credit and security deposits. These cash proceeds were recognized as lease termination fee income, which is included in rental and related revenues on the Consolidated Statements of Operations. In April 2024, the U.S. Bankruptcy Court approved the assignment and assumption of the remaining operating lease by the buyer of Sorrento’s assets. Given the nature of bankruptcy proceedings, the probability, timing, and amount of the additional proceeds, if any, that the Company may ultimately receive in connection with the claims are uncertain. Accordingly, the Company has not recorded any estimated recoveries associated with these claims as of December 31, 2024 or December 31, 2023. </context> | us-gaap:LitigationSettlementAmountAwardedFromOtherParty |
On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 (“Graphite Bio”), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio’s lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of $ 37 million, comprised of a $ 21 million termination fee and $ 16 million prepayment of Graphite Bio’s contractual rent through the amended term. The $ 37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease. | text | 37 | monetaryItemType | text: <entity> 37 </entity> <entity type> monetaryItemType </entity type> <context> On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 (“Graphite Bio”), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio’s lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of $ 37 million, comprised of a $ 21 million termination fee and $ 16 million prepayment of Graphite Bio’s contractual rent through the amended term. The $ 37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease. </context> | us-gaap:OperatingLeasePayments |
On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 (“Graphite Bio”), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio’s lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of $ 37 million, comprised of a $ 21 million termination fee and $ 16 million prepayment of Graphite Bio’s contractual rent through the amended term. The $ 37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease. | text | 16 | monetaryItemType | text: <entity> 16 </entity> <entity type> monetaryItemType </entity type> <context> On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 (“Graphite Bio”), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio’s lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of $ 37 million, comprised of a $ 21 million termination fee and $ 16 million prepayment of Graphite Bio’s contractual rent through the amended term. The $ 37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease. </context> | us-gaap:PaymentsForRent |
On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 (“Graphite Bio”), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio’s lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of $ 37 million, comprised of a $ 21 million termination fee and $ 16 million prepayment of Graphite Bio’s contractual rent through the amended term. The $ 37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease. | text | 37 | monetaryItemType | text: <entity> 37 </entity> <entity type> monetaryItemType </entity type> <context> On October 26, 2023, the Company amended its lease with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024 (“Graphite Bio”), at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio’s lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of $ 37 million, comprised of a $ 21 million termination fee and $ 16 million prepayment of Graphite Bio’s contractual rent through the amended term. The $ 37 million was recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease. </context> | us-gaap:StraightLineRentAdjustments |
As of December 31, 2024, includes net unamortized discounts of $ 3 million | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, includes net unamortized discounts of $ 3 million </context> | us-gaap:ReceivableWithImputedInterestDiscount |
$ 18 million unamortized mark-to-market discount related to the Outpatient Medical Seller Financing as discussed below. | text | 18 | monetaryItemType | text: <entity> 18 </entity> <entity type> monetaryItemType </entity type> <context> $ 18 million unamortized mark-to-market discount related to the Outpatient Medical Seller Financing as discussed below. </context> | us-gaap:ReceivableWithImputedInterestDiscount |
$ 40 million, $ 22 million, and $ 22 million, respectively, of interest income related to loans receivable in interest income and other on the Consolidated Statements of Operations. | text | 40 | monetaryItemType | text: <entity> 40 </entity> <entity type> monetaryItemType </entity type> <context> $ 40 million, $ 22 million, and $ 22 million, respectively, of interest income related to loans receivable in interest income and other on the Consolidated Statements of Operations. </context> | us-gaap:InterestIncomeOperating |
$ 40 million, $ 22 million, and $ 22 million, respectively, of interest income related to loans receivable in interest income and other on the Consolidated Statements of Operations. | text | 22 | monetaryItemType | text: <entity> 22 </entity> <entity type> monetaryItemType </entity type> <context> $ 40 million, $ 22 million, and $ 22 million, respectively, of interest income related to loans receivable in interest income and other on the Consolidated Statements of Operations. </context> | us-gaap:InterestIncomeOperating |
As of December 31, 2024, unamortized net discounts on the secured loans and mezzanine loans acquired were $ 1 million and $ 2 million, respectively. These discounts are recognized in interest income and other on the Consolidated Statements of Operations using the effective interest rate method over the remaining term of the loans. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, unamortized net discounts on the secured loans and mezzanine loans acquired were $ 1 million and $ 2 million, respectively. These discounts are recognized in interest income and other on the Consolidated Statements of Operations using the effective interest rate method over the remaining term of the loans. </context> | us-gaap:ReceivableWithImputedInterestNetAmount |
As of December 31, 2024, unamortized net discounts on the secured loans and mezzanine loans acquired were $ 1 million and $ 2 million, respectively. These discounts are recognized in interest income and other on the Consolidated Statements of Operations using the effective interest rate method over the remaining term of the loans. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, unamortized net discounts on the secured loans and mezzanine loans acquired were $ 1 million and $ 2 million, respectively. These discounts are recognized in interest income and other on the Consolidated Statements of Operations using the effective interest rate method over the remaining term of the loans. </context> | us-gaap:ReceivableWithImputedInterestNetAmount |
The Company received partial principal repayments of $ 246 million during the year ended December 31, 2021 and $ 45 million during the year ended December 31, 2022 | text | 246 | monetaryItemType | text: <entity> 246 </entity> <entity type> monetaryItemType </entity type> <context> The Company received partial principal repayments of $ 246 million during the year ended December 31, 2021 and $ 45 million during the year ended December 31, 2022 </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
The Company received partial principal repayments of $ 246 million during the year ended December 31, 2021 and $ 45 million during the year ended December 31, 2022 | text | 45 | monetaryItemType | text: <entity> 45 </entity> <entity type> monetaryItemType </entity type> <context> The Company received partial principal repayments of $ 246 million during the year ended December 31, 2021 and $ 45 million during the year ended December 31, 2022 </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million | text | 69 | monetaryItemType | text: <entity> 69 </entity> <entity type> monetaryItemType </entity type> <context> In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million | text | 4.0 | percentItemType | text: <entity> 4.0 </entity> <entity type> percentItemType </entity type> <context> In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million </context> | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million | text | 5.0 | percentItemType | text: <entity> 5.0 </entity> <entity type> percentItemType </entity type> <context> In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million </context> | us-gaap:LoansReceivableBasisSpreadOnVariableRate |
In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million | text | 5 | monetaryItemType | text: <entity> 5 </entity> <entity type> monetaryItemType </entity type> <context> In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million </context> | us-gaap:ProceedsFromCollectionOfLoansReceivable |
In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million | text | 58 | monetaryItemType | text: <entity> 58 </entity> <entity type> monetaryItemType </entity type> <context> In February 2024, this loan reached its maturity and was refinanced with the Company. In connection with the refinance, the Company received a partial principal repayment of $ 69 million and the maturity date was extended to August 2027. The interest rate on the loan remained as Term SOFR (plus a 10 basis point adjustment related to SOFR transition) plus 4.0 % for the first two years of the extended term, but increases to 5.0 % for the last 18 months of the extended term and is now subject to a fixed floor of 9 %. In connection with the refinance, the additional financing was reduced to $ 1 million, all of which was funded in February 2024. Therefore, at December 31, 2024, the Company had no commitment to provide the borrower with additional financing for capital expenditures. In May 2024, the Company received a partial principal repayment of $ 5 million in conjunction with the disposition of the underlying collateral. At December 31, 2024 and 2023, this secured loan had an outstanding principal balance of $ 58 million </context> | us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.